Fibromyalgia is one of the most prevalent rheumatologic conditions. Even though the condition is primarily characterized by chronic widespread pain, patients with fibromyalgia experience a number of associated symptoms, including mood and sleep disturbances. The search for drugs able to control all of these manifestations has been always regarded as an aim of paramount importance. However, most of these attempts have been frustrated by the complex multifactorial pathogenesis of fibromyalgia. The recently failed phase III trials of mirogabalin and cyclobenzaprine modified release (TNX-102) underline once again the difficulties of finding effective therapies. In this paper, we review the current knowledge about the pathogenesis of fibromyalgia, the ongoing trials, and the possible future scenario of this common and yet elusive condition.

Serio I., Tovoli F. (2019). Therapeutic targets to watch for fibromyalgia. DRUGS OF THE FUTURE, 44(5), 357-365 [10.1358/dof.2019.44.5.2958471].

Therapeutic targets to watch for fibromyalgia

Serio I.;Tovoli F.
2019

Abstract

Fibromyalgia is one of the most prevalent rheumatologic conditions. Even though the condition is primarily characterized by chronic widespread pain, patients with fibromyalgia experience a number of associated symptoms, including mood and sleep disturbances. The search for drugs able to control all of these manifestations has been always regarded as an aim of paramount importance. However, most of these attempts have been frustrated by the complex multifactorial pathogenesis of fibromyalgia. The recently failed phase III trials of mirogabalin and cyclobenzaprine modified release (TNX-102) underline once again the difficulties of finding effective therapies. In this paper, we review the current knowledge about the pathogenesis of fibromyalgia, the ongoing trials, and the possible future scenario of this common and yet elusive condition.
2019
Serio I., Tovoli F. (2019). Therapeutic targets to watch for fibromyalgia. DRUGS OF THE FUTURE, 44(5), 357-365 [10.1358/dof.2019.44.5.2958471].
Serio I.; Tovoli F.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/777254
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact